Download PDF
Thromb Haemost 1991; 66(05): 569-574
DOI: 10.1055/s-0038-1646461
Original Article
Schattauer GmbH Stuttgart

Pharmacokinetic and Hemostatic Properties of the Recombinant Plasminogen Activator BM 06.022 in Healthy Volunteers

U Martin
1   The Department of Pharmacology, Boehringer Mannheim GmbH, Mannheim, Germany
,
E von Möllendorff
2   The Department of Clinical Pharmacology, Boehringer Mannheim GmbH, Mannheim, Germany
,
W Akpan
2   The Department of Clinical Pharmacology, Boehringer Mannheim GmbH, Mannheim, Germany
,
R Kientsch-Engel
3   The Diagnostic Research Center, Tutzing, Germany
,
B Kaufmann
2   The Department of Clinical Pharmacology, Boehringer Mannheim GmbH, Mannheim, Germany
,
G Neugebauer
2   The Department of Clinical Pharmacology, Boehringer Mannheim GmbH, Mannheim, Germany
› Author Affiliations
Further Information

Publication History

Received 12 March 1991

Accepted 24 April 1991

Publication Date:
25 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In a randomized, single-blind, placebo-controlled, cross-over Phase-I study pharmacokinetic and hemostatic properties of BM 06.022 were investigated in seven healthy, male human volunteers. The novel recombinant plasminogen activator BM 06.022 consists of the kringle 2 domain and the protease domain of human t-PA and is unglycosylated due to its expression in Escherichia coli cells. Vehicle or 6 MU (= 10.4 mg) BM 06.022 was administered as a single i.v. bolus injection of 10 ml over 2 min. BM 06.022 was well tolerated. Fibrinogen levels and clotting times remained unchanged at baseline levels after 6 MU BM 06.022; plasminogen and α2-antiplasmin (collected on chloromethylketone) decreased maximally to 83 ± 1% and 64 ± 3%, respectively, of baseline. D-dimers and fibrinogen degradation products increased to 1,006 ± 234 ng/ml and 555 ± 155 ng/ml, respectively, after BM 06.022. Half-life of BM 06.022-activity was 11.2 ± 0.4 min and of antigen was 13.9 ± 0.7 min, followed by a terminal half-life only for antigen of 173 ± 33 min. Plasma clearance of BM 06.022 was 371 ± 13 ml/min for activity and 183 ± 15 ml/min for antigen. Thus, BM 06.022 is not fibrinogenolytic at 6 MU and is a fibrinolytic agent with a longer half-life than t-PA.

 

  • References

  • 1 Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Müller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in myocardial infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 7 6 142-54
    PubMedGoogle Scholar
  • 2 Wilcox RG, Olsson CG, Skene AM, von der Lippe G, Jensen G, Hampton JR. Trial of tissue-type plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988: 525-30
    PubMedGoogle Scholar
  • 3 Seifried E, Tanswell P, Ellbrück D, Haerer W, Schmidt A. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemostas 1989; 61: 497-501
    PubMedGoogle Scholar
  • 4 Lijnen HR, Collen D. News strategies in the development of thrombolytic agents. Blut 1988; 57: 147-62
    CrossrefPubMedGoogle Scholar
  • 5 Rijken DC, Otter M, Kuiper J, van Berkel ThJC. Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells. Thromb Res 1990; S uppl. X 63-71
    PubMedGoogle Scholar
  • 6 Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989; 73: 1842-50
    PubMedGoogle Scholar
  • 7 Collen D, Stassen JM, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-9
    PubMedGoogle Scholar
  • 8 Kohnert U, Rudolph R, Prinz H, Opitz U, Stern A, Martin U, Fischer S, Buckel P, Kresse GB. Production of a recombinant human tissue plasminogen activator variant (BM 06.022) from Escherichia coli using a novel renaturation technology. Fibrinolysis 1990; 4 (suppl. 3) 44
    PubMedGoogle Scholar
  • 9 van Zonneveld AJ, Veerman H, Pannekoek H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci 1986; 83: 4670-4
    CrossrefPubMedGoogle Scholar
  • 10 Verheijen JH, Caspers MPM, Chang GTG, de Munk GAW, Pouwels PH, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5: 3525-30
    PubMedGoogle Scholar
  • 11 Hansen L, Blue Y, Barone K, Collen D, Larsen GR. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator. J Biol Chem 1988; 263: 15713-9
    PubMedGoogle Scholar
  • 12 Wilhelm J, Kalyan NK, Lee SG, Hum WT, Rappaport R, Hung PP. Deglycosylation increases the fibrinolytic activity of a deletion mutant of tissue-type plasminogen activator. Thromb Haemostas 1990; 63: 464-71
    PubMedGoogle Scholar
  • 13 Rijken DC, Groeneveld E. Isolation and functional characterization of the heavy and light chain of human tissue-type plasminogen activator. J Biol Chem 1986; 261: 3098-102
    PubMedGoogle Scholar
  • 14 Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, Stern A, Strein K. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemostas 1991; 65: 560-4
    PubMedGoogle Scholar
  • 15 Martin U, Fischer S, Kohnert U, Lill H, Rudolph R, Sponer G, Stern A, Strein K. Thrombolytic potency of an E. coli-produced novel variant of rt-PA in dogs. Fibrinolysis 1990; 4 (suppl. 3) 9
    PubMedGoogle Scholar
  • 16 Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K. Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. Thromb Res 1991; 62: 137-46
    CrossrefPubMedGoogle Scholar
  • 17 Martin U, Sponer G, Strein K. Coronary thrombolytic properties of the recombinant plasminogen activator BM 06.022 in dogs. Ann Hematol 1991; 62: A75
    PubMedGoogle Scholar
  • 18 Martin U, von Möllendorff E, Akpan W, Neugebauer G. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Ann Hematol 1991; 62: A43
    PubMedGoogle Scholar
  • 19 Rudolph R, Fischer S, Mattes R. European patent application 219874.
    PubMedGoogle Scholar
  • 20 Lill H. Biochemische und physiologische Grundlagen zum Gewebe-Plasminogenaktivator (t-PA). Z Gesamte Inn Med 1987; 42: 478-86
    PubMedGoogle Scholar
  • 21 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable for measurements in plasma. Thromb Haemostas 1982; 48: 266-9
    PubMedGoogle Scholar
  • 22 Mohler MA, Refino CF, Chen SA, Chen AB, Hotchkiss AJ. D-phepro-arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemostas 1986; 56: 160-4
    PubMedGoogle Scholar
  • 23 Seifried E, Tanswell P. Comparison of specific antibody, d-phe-proarg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters. Thromb Haemostas 1987; 58: 921-6
    PubMedGoogle Scholar
  • 24 Stump DC, Topol EJ, Chen AB, Hopkins A, Collen D. Monitoring of hemosfasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator. Thromb Haemostas 1988; 59: 133-7
    PubMedGoogle Scholar
  • 25 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46
    CrossrefPubMedGoogle Scholar
  • 26 Collen D. Inhibitors of fibrinolysis. In: Fibrinolysis.. Kline DL, Reddy KNN. (eds) CRC Press, Inc., Boca Raton, FL: 1980. pp 129-49
    Google Scholar
  • 27 Wallen P. Biochemistry of plasminogen. In: Fibrinolysis.. Kline DL, Reddy KNN. (eds) CRC Press, Inc., Boca Raton, FL: 1980. pp 1-24
    Google Scholar
  • 28 Tanswell P, Seifried E, Su PCAF, Feuerer W, Rijken DC. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther 1989; 46: 155-62
    CrossrefPubMedGoogle Scholar
  • 29 Marder J, Rothbard RL, Fitzpatrick PG, Francis CW, Norry EC. Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction. Drugs 1987; 33 (suppl. 3) 124-32
    CrossrefPubMedGoogle Scholar
  • 30 Seifried E, Tanswell P, Rijken DC, Barrett-Bergshoeff MM, Su CAPF, Kluft C. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Drug Res 1988; 38: 418-22
    PubMedGoogle Scholar
  • 31 Tebbe U, Tanswell P, Seifried E, Feuerer W, Scholz K-H, Herrmann KS. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1989; 64: 448-53
    CrossrefPubMedGoogle Scholar
  • 32 Verstraete M, van de Werf F, Tranchesi B, Chamone DF, Pelaggi F. Bolus alteplase. Lancet II 1989: 989-90
    PubMedGoogle Scholar